Bristol-Myers Squibb (NYSE:BMY) Shares Up 0.3%

Bristol-Myers Squibb (NYSE:BMY) shares rose 0.3% during trading on Friday . The company traded as high as $44.33 and last traded at $43.83. Approximately 3,174,975 shares traded hands during trading, a decline of 80% from the average daily volume of 15,808,061 shares. The stock had previously closed at $43.70.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on BMY shares. Wells Fargo & Company increased their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 18th. Redburn Atlantic cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price target for the company from $77.00 to $54.00 in a report on Tuesday, February 6th. BMO Capital Markets cut their price objective on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a report on Friday, April 26th. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. Finally, Societe Generale cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus target price of $60.00.

Bristol-Myers Squibb Trading Up 0.7 %

The firm’s 50-day simple moving average is $50.37 and its 200-day simple moving average is $50.74. The firm has a market capitalization of $89.17 billion, a PE ratio of -14.19, a price-to-earnings-growth ratio of 14.72 and a beta of 0.45. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, beating the consensus estimate of ($4.53) by $0.13. The company had revenue of $11.87 billion during the quarter, compared to analysts’ expectations of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. Bristol-Myers Squibb’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period in the prior year, the business posted $2.05 EPS. Equities analysts expect that Bristol-Myers Squibb will post 0.59 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, May 1st. Investors of record on Friday, April 5th were issued a dividend of $0.60 per share. The ex-dividend date of this dividend was Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a yield of 5.46%. Bristol-Myers Squibb’s dividend payout ratio is currently -77.42%.

Hedge Funds Weigh In On Bristol-Myers Squibb

A number of hedge funds have recently modified their holdings of BMY. Concord Wealth Partners lifted its stake in Bristol-Myers Squibb by 6.6% in the third quarter. Concord Wealth Partners now owns 21,619 shares of the biopharmaceutical company’s stock worth $1,255,000 after acquiring an additional 1,330 shares during the period. Lindbrook Capital LLC boosted its stake in shares of Bristol-Myers Squibb by 2.3% during the 3rd quarter. Lindbrook Capital LLC now owns 8,060 shares of the biopharmaceutical company’s stock valued at $468,000 after purchasing an additional 182 shares in the last quarter. ETF Store Inc. purchased a new position in shares of Bristol-Myers Squibb during the third quarter valued at about $215,000. Taylor Frigon Capital Management LLC raised its stake in Bristol-Myers Squibb by 2.8% in the third quarter. Taylor Frigon Capital Management LLC now owns 19,968 shares of the biopharmaceutical company’s stock worth $1,159,000 after buying an additional 535 shares in the last quarter. Finally, BluePath Capital Management LLC bought a new stake in Bristol-Myers Squibb during the 3rd quarter valued at approximately $52,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.